|
|
|
| home > ebr > Winter 2011 |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
|
 |
| |
|
|
|
|
Partnering is the lifeblood of the biotech and pharmaceutical industries and, as the industry expands, Robert Lee Kilpatrick from TVG discusses the ideal elements for successful collaborations.
|
|
|
Neil Johnson, Ad Rietveld and Chloë Brown of RJW & Partners Ltd consider the benefits of thorough in-licensing evaluation and early understanding of payers' perspectives in guaranteeing launch success.
|
|
|
|
|
Xavier Tizon at Oncodesign makes a strong case for the untapped potential of imaging biomarkers and how they can be applied in future drug development stages.
|
|
|
Simon Webster from Avacta Group PLC considers the benefits of maintaining physical stability of candidate therapeutic proteins at an early stage in the discovery process, and highlights pioneering techniques for monitoring conformational and colloidal stability.
|
|
|
|
For companies facing up to the move from proof-of-concept to proof-of-differentiation, Markus Thunecke from Catenion considers the three levels of evaluation that should be considered.
|
|
|
Kai Lamottke at Bicoll GmbH, Christophe Ripoll at Naturalpha and Robert Walczak at Genfit SA consider if natural product programmes are ready to challenge the traditional drug cycle process.
|
|
|
By encouraging others to develop their own drugs using a patented technology, the patent owner has the potential to develop substantial revenues, observe Michael R Ward,Otis Littlefield and Anita Choi from Morrison & Foerster LLP.
|
|
|
Sekhar Medisetti at GlobalData takes a look at the niche market for Type 1 diabetes, the continuous challenge posed by patient compliance, and the problematic issue of delivery methods for insulin products.
|
|
|
|
Bill Whitford of Thermo Scientific Cell Culture and BioProcessing analyses the advantages of single-use bioreactors and the supply and performance features they offer in process development.
|
|
|
| In response to the danger posed by bacterial retention testing, Martha Folmsbee, Morven McAlister and Jerold Martin at Pall Life Sciences compare and contrast the various tests for predicting and confirming retention. |
|
|
Amin Omar at Innovotech highlights the need for finding the most suitable antimicrobial agent to avoid the potential problems of biofilm infections.
|
|
|
|
Following the launch of the Smart SME Market Validation Programme, Rebecca Philpot from the State Government of Victoria, Australia, considers other ways in which the city is changing to better accommodate the biotech industry.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
WORLD’S FIRST PCM CARGO COVER
A British team of scientists at TLX Cargo Ltd have invented the worlds Cargo Cover/Thermal blanket that incorporates Phase Change Material (PCM) into it`s structure, solved the problem of hot lane temperature excursions on the tarmac.
More info >> |
|
 |
White Papers |
 |
|
Data Technology as a Catalyst for Growth in the Life Sciences
AIGENPULSE
The life sciences industry is changing at a rapid pace. The need to develop the next blockbuster is pushing current technologies and methodologies to the limit. Scientific advancement over the last decades was embossed with giant leaps in knowledge, however, the new reality is that smaller incremental gains need to be carved out with ever increasing investments. In order to survive, progress and prosper in this new reality, a holistic approach to getting the most of research data is crucial. In fact, it will likely be the difference of being in existence in 5-10 years or not. For those bold enough to step into an area they are unfamiliar with, huge rewards are waiting.
More info >> |
|
 |
Industry Events |
 |
Outsourcing in Clinical Trials Medical Device USA 2018
11-12 July 2018, Minneapolis, Minnesota
6th Outsourcing in Clinical
Trials conference is the only clinical outsourcing platform for medical device
companies within Medical Alley this year.
More info >> |
|
|
